Botswana vs Zimbabwe: Share of the population living with HIV receiving antiretroviral therapy
Botswana
95.2%
in 2024
Zimbabwe
95.1%
in 2024
Botswana rank
2nd
Zimbabwe rank
4th
Share of the population living with HIV receiving antiretroviral therapy over time
- Botswana
- Zimbabwe
How they compare
Botswana currently reports 95.2% against 95.1% in Zimbabwe, a difference of 0.1%.
The two have swapped places 3 times across 35 shared years of data; in 1990 it was Zimbabwe ahead.
Botswana ranks 2nd and Zimbabwe ranks 4th of 149 countries.
Across the 4 decades both report, Botswana averaged higher in 3 and Zimbabwe in 1.
Head to head by decade
| Decade | Botswana | Zimbabwe | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 1.4% | 1.3% | Zimbabwe |
| 2000s | 17.4% | 5.3% | 12.1% | Botswana |
| 2010s | 69.4% | 57.4% | 11.9% | Botswana |
| 2020s | 92.6% | 92.0% | 0.6% | Botswana |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Botswana or Zimbabwe?
- Botswana, at 95.2% against 95.1% in Zimbabwe as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Botswana and Zimbabwe?
- 0.1%, with Botswana ahead.
- How many years of comparable data are there for Botswana and Zimbabwe?
- 35 years are reported by both, from 1990 to 2024.
- How do Botswana and Zimbabwe rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Botswana ranks 2nd and Zimbabwe ranks 4th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.